Table 1.
Discovery set (N=16) | Validation set (N=15) |
|
Sex | ||
Female | 5 (31%) | 4 (27%) |
Male | 11 (69%) | 11 (73%) |
Age | ||
≥66 | 9 (56%) | 7 (47%) |
<66 | 7 (44%) | 8 (53%) |
Therapy line | ||
Second | 13 (81%) | 12 (75%) |
Third | 3 (19%) | 3 (25%) |
First-line TKI | ||
Sunitinib | 11 (69%) | 8 (53%) |
Pazopanib | 5 (31%) | 7 (47%) |
IMDC score | ||
Good risk | 5 (31%) | 5 (33%) |
Intermediate risk | 11 (69%) | 10 (67%) |
IMDC, International Metastatic RCC Database Consortium; TKI, tyrosine kinase inhibitor.